BB
CELG

BB Biotech’s Celgene Corp CELG Stock Holding History

BB Biotech’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$208M Sell
2,200,000
-103,875
-5% -$9.08M 5.22% 6
2018
Q4 		$148M Sell
2,303,875
-680,423
-23% -$50.2M 4.73% 6
2018
Q3 		$267M Sell
2,984,298
-340,000
-10% -$30M 7.07% 3
2018
Q2 		$264M Hold
3,324,298
– – 7.62% 3
2018
Q1 		$297M Sell
3,324,298
-100,000
-3% -$9.6M 8.2% 3
2017
Q4 		$357M Buy
3,424,298
+240,000
+8% +$27.1M 10.06% 2
2017
Q3 		$464M Sell
3,184,298
-65,000
-2% -$8.85M 12.85% 1
2017
Q2 		$422M Sell
3,249,298
-90,000
-3% -$11M 12.9% 2
2017
Q1 		$416M Sell
3,339,298
-120,000
-3% -$14.4M 13.59% 2
2016
Q4 		$400M Hold
3,459,298
– – 14.83% 1
2016
Q3 		$362M Sell
3,459,298
-150,000
-4% -$16.2M 12.71% 2
2016
Q2 		$356M Hold
3,609,298
– – 14.05% 1
2016
Q1 		$361M Hold
3,609,298
– – 14.36% 1
2015
Q4 		$432M Buy
3,609,298
+20,000
+0.6% +$2.31M 12.18% 1
2015
Q3 		$388M Buy
3,589,298
+25,000
+0.7% +$3.1M 12.31% 2
2015
Q2 		$413M Buy
3,564,298
+10,000
+0.3% +$1.14M 11.18% 1
2015
Q1 		$410M Sell
3,554,298
-160,000
-4% -$19.1M 12.21% 1
2014
Q4 		$415M Sell
3,714,298
-175,000
-4% -$18.5M 13.46% 1
2014
Q3 		$369M Sell
3,889,298
-330,000
-8% -$29.8M 14.99% 1
2014
Q2 		$362M Sell
4,219,298
-150,000
-3% -$11.4M 17.22% 1
2014
Q1 		$305M Buy
4,369,298
+310,756
+8% +$24.6M 15.72% 1
2013
Q4 		$343M Buy
4,058,542
+60,000
+2% +$4.75M 18.32% 1
2013
Q3 		$308M Sell
3,998,542
-301,830
-7% -$21.2M 16.77% 1
2013
Q2 		$252M Buy
+4,300,372
New +$259M 18.12% 1

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BB Biotech's CELG Position: Q1 2019 in Review

BB Biotech reduced its Celgene Corp (CELG) stake by 4.5% in Q1 2019, selling an estimated $9.08M and leaving 2,200,000 shares worth $208M. The position accounts for 5.22% of the portfolio, ranked #6.

BB Biotech first reported a position in CELG in Q2 2013 and has held it in 24 quarters since. The position peaked at $464M in Q3 2017. 1,389 funds tracked by Wall St. Rank hold CELG as of Q1 2019.

  • BB Biotech held 2,200,000 shares of Celgene Corp worth $208M as of Q1 2019.
  • BB Biotech sold 103,875 Celgene Corp shares in Q1 2019, an estimated $9.08M.
  • Celgene Corp made up 5.22% of BB Biotech's portfolio in Q1 2019, its #6 holding.
  • BB Biotech first reported a position in Celgene Corp in Q2 2013 and has held it in 24 quarters since.
  • BB Biotech's Celgene Corp position peaked at $464M in Q3 2017.
  • 1,389 funds tracked by Wall St. Rank held Celgene Corp as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.